MA54940A - Dérivés d'acides aminés pour le traitement de maladies inflammatoires - Google Patents
Dérivés d'acides aminés pour le traitement de maladies inflammatoiresInfo
- Publication number
- MA54940A MA54940A MA054940A MA54940A MA54940A MA 54940 A MA54940 A MA 54940A MA 054940 A MA054940 A MA 054940A MA 54940 A MA54940 A MA 54940A MA 54940 A MA54940 A MA 54940A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- amino acid
- acid derivatives
- inflammatory diseases
- inflammatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795549P | 2019-01-22 | 2019-01-22 | |
| US201962871951P | 2019-07-09 | 2019-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54940A true MA54940A (fr) | 2021-12-22 |
Family
ID=69726748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054940A MA54940A (fr) | 2019-01-22 | 2020-01-22 | Dérivés d'acides aminés pour le traitement de maladies inflammatoires |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220081415A1 (fr) |
| EP (1) | EP3924349A2 (fr) |
| JP (1) | JP2022524571A (fr) |
| KR (1) | KR20210141930A (fr) |
| CN (1) | CN113614074A (fr) |
| AU (1) | AU2020211980A1 (fr) |
| BR (1) | BR112021014372A2 (fr) |
| CA (1) | CA3127246A1 (fr) |
| CL (1) | CL2021001944A1 (fr) |
| CO (1) | CO2021010931A2 (fr) |
| EC (1) | ECSP21062210A (fr) |
| IL (1) | IL284980A (fr) |
| MA (1) | MA54940A (fr) |
| MX (1) | MX2021008748A (fr) |
| SG (1) | SG11202107977TA (fr) |
| WO (1) | WO2020154420A2 (fr) |
| ZA (1) | ZA202105229B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022511469A (ja) | 2018-11-30 | 2022-01-31 | コメット セラピューティクス インコーポレイテッド | 環状パンテテイン誘導体及びその使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US6218390B1 (en) * | 1998-12-17 | 2001-04-17 | Synaptic Pharmaceutical Corporation | Morpholinone and morpholine derivatives and uses thereof |
| WO2010127058A1 (fr) * | 2009-05-01 | 2010-11-04 | Profectus Biosciences, Inc. | Dérivés de benzamide et de naphtamide inhibant le facteur nucléaire kappa(b) (nf-kb) |
-
2020
- 2020-01-22 SG SG11202107977TA patent/SG11202107977TA/en unknown
- 2020-01-22 BR BR112021014372-6A patent/BR112021014372A2/pt unknown
- 2020-01-22 CN CN202080021880.4A patent/CN113614074A/zh active Pending
- 2020-01-22 MX MX2021008748A patent/MX2021008748A/es unknown
- 2020-01-22 CA CA3127246A patent/CA3127246A1/fr active Pending
- 2020-01-22 WO PCT/US2020/014636 patent/WO2020154420A2/fr unknown
- 2020-01-22 JP JP2021543302A patent/JP2022524571A/ja active Pending
- 2020-01-22 MA MA054940A patent/MA54940A/fr unknown
- 2020-01-22 AU AU2020211980A patent/AU2020211980A1/en active Pending
- 2020-01-22 KR KR1020217026302A patent/KR20210141930A/ko unknown
- 2020-01-22 EP EP20708296.7A patent/EP3924349A2/fr active Pending
- 2020-01-22 US US17/424,455 patent/US20220081415A1/en active Pending
-
2021
- 2021-07-20 IL IL284980A patent/IL284980A/en unknown
- 2021-07-22 CL CL2021001944A patent/CL2021001944A1/es unknown
- 2021-07-23 ZA ZA2021/05229A patent/ZA202105229B/en unknown
- 2021-08-19 CO CONC2021/0010931A patent/CO2021010931A2/es unknown
- 2021-08-20 EC ECSENADI202162210A patent/ECSP21062210A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3127246A1 (fr) | 2020-07-30 |
| KR20210141930A (ko) | 2021-11-23 |
| WO2020154420A3 (fr) | 2020-09-10 |
| CN113614074A (zh) | 2021-11-05 |
| CO2021010931A2 (es) | 2022-01-17 |
| EP3924349A2 (fr) | 2021-12-22 |
| ECSP21062210A (es) | 2022-06-30 |
| IL284980A (en) | 2021-09-30 |
| BR112021014372A2 (pt) | 2021-09-28 |
| SG11202107977TA (en) | 2021-08-30 |
| MX2021008748A (es) | 2022-01-24 |
| WO2020154420A2 (fr) | 2020-07-30 |
| CL2021001944A1 (es) | 2022-05-06 |
| US20220081415A1 (en) | 2022-03-17 |
| ZA202105229B (en) | 2022-12-21 |
| AU2020211980A1 (en) | 2021-08-19 |
| WO2020154420A4 (fr) | 2020-11-12 |
| JP2022524571A (ja) | 2022-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55560A (fr) | Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer | |
| MA50763A (fr) | Compositions d'acides aminés et méthodés de traitement de maladies et troubles musculaires | |
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA54515A (fr) | Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires | |
| MX2018005694A (es) | 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas. | |
| MA55325A (fr) | Composés pour le traitement de maladies pd-l1 | |
| PH12018500087A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| MA55604A (fr) | Dérivés de pyrrolotriazine pour le traitement de maladies médiées par kit et pdgfra | |
| MA51524A (fr) | Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques | |
| MX2019008690A (es) | Compuestos espiro heterociclicos como inhibidores de magl. | |
| MA56387A (fr) | Dérivés de quinazoline-4-one utiles pour le traitement de maladies et de troubles associés à braf | |
| MA56019A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA49906A (fr) | Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie | |
| ATE549338T1 (de) | Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind | |
| MA53614A (fr) | Protéine pour le traitement de maladies inflammatoires | |
| MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MX2019008626A (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl). | |
| MX2020009235A (es) | Formulacion oftalmica. | |
| MA43828A (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
| FR3084254B1 (fr) | Derives deuteres du lanifibranor | |
| MA52415A (fr) | Dérivés de triazine pour le traitement de maladies associées à des neurotrophines | |
| MA53501A (fr) | Inhibiteurs de pde9 pour le traitement de la drépanocytose | |
| MA51558A (fr) | Dérivés de 2,4,6,7-tétrahydro-pyrazolo[4,3-d]pyrimidin-5-one et composés apparentés en tant que modulateurs du récepteur c5a pour le traitement de la vascularite et de maladies inflammatoires | |
| EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта | |
| MA55490A (fr) | Mutéine de lipocaline pour le traitement de l'asthme |